Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure: Table 1-Reference-Cited by-同舟云学术

Academic-industrial collaboration in the development of the first angiotensin receptor blocker: neprilysin inhibitor in the treatment of heart failure: Table 1

Published:2016-03-01 Issue:9 Volume:37 Page:745-746
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:Eur Heart J

Author:

Braunwald Eugene

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/37/9/745/7112324/ehw055.pdf

Reference20 articles.

1. PARADIGM-HF trial of Novartis' LCZ696 for chronic heart failure closes early based on strength of interim results. Novartis press release. March 31, 2014. http://www.novartis.com/newsroom/media-releases/en/2014/1772754.shtml ( 5 August 2015) (†)

2. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

3. Paradigm Shifts in Heart-Failure Therapy — A Timeline

4. The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure

5. Niere und Kreislauf1

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION;Rational Pharmacotherapy in Cardiology;2018-05-01

2. Sacubitril/valsartan: um importante avanço no puzzle terapêutico da insuficiência cardíaca;Revista Portuguesa de Cardiologia;2017-09

3. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure;Revista Portuguesa de Cardiologia (English Edition);2017-09

4. Ethical Issues – the challenge to keep up with a changing environment;European Heart Journal;2016-03-01